Drugging Undruggable Molecular Cancer Targets

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 23-40

  Lazo, John S ^a   Sharlow, Elizabeth R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer drug targets; Oncogenes; Phosphatases; RAS; Transcription factors

Indexed keywords

MAX PROTEIN; MYC PROTEIN; PHOSPHATASE; PHOSPHOSERINE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RAS PROTEIN; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; HUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNDRUGGABLE MOLECULAR CANCER TARGET; ANIMAL; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84954170474     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103440     Document Type: Article

References (101)

1. Jarvis LM. 2015. The year in new drugs. Chem. Eng. News 93:11-16
2. Russ AP, Lampel S. 2005. The druggable genome: An update. Drug Discov. Today 10:1607-10
3. Overington JP, Al-Lazikani B, Hopkins AL. 2006. How many drug targets are there? Nat. Rev. Drug Discov. 5:993-96
4. Pert CB, Snyder SH. 1973. Opiate receptor: demonstration in nervous tissue. Science 179:1011-14
5. DeCosta BR, Rothman RB, Bykov V, Jacobson AE, Rice KC. 1989. Selective and enantiospecific acylation ofopioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide. Demonstration ofreceptor heterogeneity. J. Med. Chem. 32:281-83
6. Striessnig J, Murphy BJ, Catterall WA. 1991. Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the1 subunit. PNAS 88:10769-73
7. Tsang CK, Qi H, Liu LF, Zheng XFS. 2007. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12:112-14
8. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, et al. 1990. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. PNAS 87:9231-35
9. Rask-Andersen M, Masuram S, Schiöth HB. 2014. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54:9-26
10. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. 2014. Only three driver gene mutations are required for the development of lung and colorectal cancers. PNAS 112:118-23
11. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJ, Kinzler KW. 2013. Cancer genome landscapes. Science 339:1546-58
12. Hu J, Locasale JW, Bielas JH, O'Sullivan J, Sheahan K, et al. 2013. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31:522-29
13. Childs-Disney JL, Disney MD. 2016. Approaches to validate and manipulate RNA targets with small molecules in cells. Annu. Rev. Pharmacol. Toxicol. 56:123-40
14. Bobbin ML, Rossi JJ. 2016. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu. Rev. Pharmacol. Toxicol. 56:103-22
15. Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, et al. 2015. HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem. Biol. 10:1831-37
16. Haberman Y, Amariglio N, Rechavi G, Eisenberg E. 2008. Trinucleotide repeats are prevalent among cancer-related genes. Trends Genet. 24:14018
17. Yu S, Liang Y, Palacino J, Difiglia M, Lu B. 2014. Drugging unconventional targets: insights from Huntington's disease. Trends Pharmacol. Sci. 35:53-62
18. Heinrich R, Neel BG, Rapoport TA. 2002. Mathematical models of protein kinase signal transduction. Mol. Cell 9:957-70
19. MacKeigan JP,Murphy LO, Blenis J. 2005. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7:591-600
20. Pharm. Res. Manuf. Am. 2014. Nearly 800 medicines and vaccines in clinical testing for cancer offer new hope to patients. Rep., PhRMA, Washington, DC. http://www. phrma. org/sites/default/files/pdf/2014-cancer-report. pdf
21. Brautigan DL. 2013. Protein Ser/Thr phosphatases-the ugly ducklings of cell signalling. FEBS J. 280:324-45
22. De Munter S, Köhn M, Bollen M. 2013. Challenges and opportunities in the development of protein phosphatase-directed therapeutics. ACS Chem. Biol. 18:36-45
23. Tonks NK. 2013. Protein tyrosine phosphatases-from housekeeping enzymes to master regulators of signal transduction. FEBS J. 280(2):346-78
24. Blaskovich MAT. 2009. Drug discovery and protein tyrosine phosphatases. Curr. Med. Chem. 16:2095-176
25. Lazo JS,Wipf P. 2009. Phosphatases as targets for cancer treatment. Curr. Opin. Investig. Drugs 10:1297-304
26. Emelyanov A, Bulavin DV. 2015. Wip1 phosphatase in breast cancer. Oncogene 34:4429-38
27. Hayashi R, Tanoue K, Durell SR, Chatterjee DK, Jenkins LM, et al. 2011. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry 50:4537-49
28. Gilmartin AG, Faitg TH, Richter M, Groy A, Seefeld MA, et al. 2014. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat. Chem. Biol. 10:181-87
29. Yagi H, Chuman Y, Kozakai Y, Imagawa T, Takahashi Y, et al. 2012. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D. Bioorg. Med. Chem. Lett. 22:729-32
30. Rayter S, Elliott R, Travers J,RowlandsMG,Richardson TB, et al. 2007. Achemical inhibitor ofPPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27:1036-44
31. Theobald B, Bonness K, Musiyenko A, Andrews JF, Urban G, et al. 2013. Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death. Mol. Cancer Res. 11:845-55
32. Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, Anderson H. 1994. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res. 54:6115-21
33. Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, et al. 2013. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin. Cancer Res. 19:4422-32
34. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, et al. 2010. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 70:5438-47
35. Chen L, Luo LF, Lu J, Li L, Liu YF, et al. 2014. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. PLOS ONE 9:e103033
36. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, et al. 2014. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. PNAS 111:9157-62
37. Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, et al. 2014. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28:1915-18
38. Perrotti D, Neviani R. 2014. SETing OP449 into the PP2A-activating drug family. Clin. Cancer Res. 20:2026-28
39. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, et al. 2014. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin. Cancer Res. 20:2092-103
40. Julien SG, DubéN,Hardy S, Tremblay ML. 2011. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11:35-49
41. Martin KR, Narang P, Medina-Franco JL, Meurice N, MacKeigan JP. 2014. Integrating virtual and biochemical screening for protein tyrosine phosphatase inhibitor discovery. Methods 15:219-28
42. Lessard L, Stuible M, Tremblay ML. 2010. The two faces of PTP1B in cancer. Biochim. Biophys. Acta 1804:613-19
43. Julien SG, DubéN, ReadM, Penney J, PaquetM, et al. 2007. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat. Genet. 39:338-46
44. Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala SD, et al. 2014. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat. Chem. Biol. 10:558-66
45. Brenner AK, Reikvam H, Lavecchia A, Bruserud Ø. 2014. Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia-the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules 19(11):18414-47
46. Rosenker KMG, Paquette WD, Johnston PA, Sharlow ER, Vogt A, et al. 2015. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorg. Med. Chem. 23(12):2810-18
47. Campbell AM, Zhang ZY. 2014. Phosphatase of regenerating liver: A novel target for cancer therapy. Expert Opin. Ther. Targets 18:555-69
48. Sharlow ER, Wipf P, McQueeney KE, Bakan A, Lazo JS. 2014. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents. Expert Opin. Investig. Drugs 23:661-73
49. Guo K, Li J, Tang JP, Tan CP, Hong CW, et al. 2011. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med. 3:99ra85
50. Guo K, Tang JP, Jie L, Al-Aidaroos AQ,Hong CW, et al. 2012. Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3:158-71
51. Maehama T,Dixon JE. 1999. PTEN: A tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:125-28
52. Song MS, Salmena L, Pandolfi PP. 2012. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13:283-96
53. Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, et al. 2014. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem. Rev. 114:6844-79
54. Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, et al. 2014. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia 28:543-53
55. Martins LR, Lúcio P, Melão A, Antunes I, Cardoso BA, et al. 2014. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 28:178-82
56. Chen BJ, Wu YL, Tanaka Y, Zhang W. 2014. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int. J. Biol. Sci. 10:1084-96
57. Prochownik EV, Vogt PK. 2010. Therapeutic targeting of Myc. Genes Cancer 1:650-59
58. YinX,Giap C, Lazo JS, Prochownik EV. 2003. Lowmolecular weight inhibitors of Myc-Max interaction and function. Oncogene 22:6151-59
59. Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, et al. 2014. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J. Natl. Cancer Inst. 106:dju320
60. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, et al. 2011. The action mechanism of the Myc inhibitor termed Omomycmay give clues on how to targetMyc for cancer therapy. PLOS ONE 6:e22284
61. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. 1998. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17:2463-72
62. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, Nasi S. 2002. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 62:3507-10
63. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, et al. 2014. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat. Commun. 5:4632
64. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, et al. 2013. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 27:504-13
65. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904-17
66. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, et al. 2011. TargetingMYC dependence in cancer by inhibiting BET bromodomains. PNAS 108:16669-74
67. JiangH, Bower KE, Beuscher IV AE, Zhou B, Bobkov AA, et al. 2009. Stabilizers of theMax homodimer identified in virtual ligand screening inhibit Myc function. Mol. Pharmacol. 76:491-502
68. Khoo KH, Chandra S, Verma CS, Lane DP. 2014. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13:217-36
69. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. 2014. p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40:1153-60
70. Chen F, Wang W, El-Deiry WS. 2010. Current strategies to target p53 in cancer. Biochem. Pharmacol. 80:724-30
71. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. 2009. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 9:862-73
72. Sun D, Li Z, Rew Y, GribbleM, BartbergerMD, et al. 2014. Discovery of AMG232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57:1454-72
73. Wang S, Sun W, Zhao Y, McEachern D, Meaux I, et al. 2014. SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 74:5855-65
74. Zhao Y, Bernard D,Wang S. 2013. Small molecule inhibitors of MDM2-p53 andMDMX-p53 interactions as new cancer therapeutics. BioDiscovery 8:4
75. Quintás-Cardama A, Verstovsek S. 2013. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res. 19:1933-40
76. Johnston PA, SenM,Hua Y, Camarco D, Shun TY, et al. 2014. High content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev. Technol. 12:55-79
77. LaPorte MG, da Paz Lima DJ, Zhang F, Sen M, Grandis JR, et al. 2014. 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorg. Med. Chem. Lett. 24:5081-85
78. Don-Doncow N, Escobar Z, JohanssonM, Kjellström S, Garcia V, et al. 2014. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J. Biol. Chem. 289:15969-78
79. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A. 2008. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 68:269-80
80. Krueger AB, Drasin D, Lea WA, Patrick AN, Patnaik S, et al. 2014. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. J. Biol. Chem. 289:16349-61
81. Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, et al. 2013. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. J. Biomol. Screen. 18:85-96
82. Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, et al. 2015. Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBF-SMMHC delays leukemia in mice. Science 347:779-84
83. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. 2014. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13:828-51
84. Thompson H. 2013. US National Cancer Institute's new RAS project targets an old foe. Nat. Med. 19:949-50
85. Chin L, Tam A, Pomerantz J, Wong M, Holash J, et al. 1998. Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-72
86. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, et al. 2012. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. PNAS 109:5299-304
87. Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA. 2014. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene 33:5442-49
88. Vigil D, Cherfils J,RossmanKL, DerCJ. 2010. RAS superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10:842-57
89. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, et al. 2010. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Investig. New Drugs 30:3291-99
90. CrewsCM, Buckley DL. 2014. Small-molecule control of intracellular protein levels throughmodulation of the ubiquitin proteasome system. Angew. Chem. Int. Ed. Engl. 53:2313-30
91. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, et al. 2014. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10:1006-12
92. Chuman Y, Yagi H, Fukuda T, Nomura T, Matsukizono M, et al. 2008. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Protein Pept. Lett. 15:938-48
93. Liang Ma L, Wen Z-S, Liu Z, Hu Z, Ma J, et al. 2011. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLOS ONE 6(5):e20159
94. Cristobal I,Manso R, Rincón R, Caramés C, Senin C, et al. 2014. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol. Cancer Ther. 13:938-47
95. Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, et al. 2009. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (12-13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J. Pharmacol. Exp. Ther. 331:45-53
96. Zhang X, He Y, Liu S, Yu Z, Jiang Z-X, et al. 2010. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53:2482-93
97. Zeng L-F, Zhang R-Y, Yu Z-H, Sijiu Li, Wu L, et al. 2014. Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J. Med. Chem. 57:6594-609
98. Mattila E, Marttila H, Sahlberg N, Kohonen P, Tähtinen S, et al. 2010. Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer 10:7
99. Daouti S, LiWH, Qian H, Huang KS, Holmgren J, et al. 2008. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 68:1162-69
100. Min G, Lee SK, Kim HN, Han YM, Lee RH, et al. 2013. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg. Med. Chem. Lett. 23:3769-74
101. Ortuso F, Paduano F, Carotenuto A, Gomez-Monterrey I, Bilotta A, et al. 2013. Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation. ACS Chem. Biol. 8:1497-506